Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25280861 | 1.00 | NPC1 (0.48) | NPC1RAB9AMAPK14FOLH1MAPK1 | |
| Hydrochloric Acid SCHEMBL32665592 | 0.87 | NPC1 (0.48) | NPC1RAB9AMAPK14FOLH1MAPK1 | |
| Hydrochloric Acid SCHEMBL32665078 | 0.85 | MAPK14 (0.44) | MAPK14TERT | |
| Hydrochloric Acid SCHEMBL32665469 | 0.85 | MAPK14 (0.44) | MAPK14TERT | |
| SCHEMBL19746730 | 0.84 | CA2 (0.50) | MAPK14FOLH1MAPK1CA2CA1 | |
| SCHEMBL25698623 | 0.82 | NPC1 (0.47) | NPC1RAB9AMAPK14FOLH1MAPK1 | |
| SCHEMBL23244680 | 0.80 | CA2 (0.51) | MAPK14FOLH1CA2CA1 | |
| SCHEMBL23244681 | 0.80 | CA2 (0.51) | MAPK14FOLH1CA2CA1 | |
| SCHEMBL28502970 | 0.80 | CA2 (0.65) | CA2CA1 | |
| SCHEMBL23244679 | 0.80 | CA2 (0.51) | MAPK14FOLH1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250283138-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-11 | — | — | US | disclosed |
| EP-4532564-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | Enlaza Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4452333-A1 | CROSSLINKING ANTIBODIES | Enlaza Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4301767-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023230582-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230582-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-117098768-A | Biologically reactive compounds and methods of use thereof | 加利福尼亚大学董事会 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023122753-A1 | CROSSLINKING ANTIBODIES | ENLAZA THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122753-A1 | CROSSLINKING ANTIBODIES | ENLAZA THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022187273-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | FCGR3B, FCGR2A, CD22 | NPC1 4020/4885RAB9A 2826/4885MAPK14 4496/4885 |
| US-20250283138-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | BCAT2, BCAT1, AADAT | NPC1 3312/4885RAB9A 2617/4885MAPK14 3962/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | NPC1 3973/4885RAB9A 1980/4885MAPK14 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.